Urgent

Eosinophilic granulomatosis with polyangiitis

EGPA / Churg-Strauss · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

EGPA is an ANCA-associated small-vessel vasculitis featuring asthma, marked eosinophilia and multisystem involvement (lung, nerve, heart, skin, GI). It often emerges in difficult asthma; cardiac and neurological involvement drive mortality and dictate treatment intensity.

Red flags

  • Cardiac involvement (heart failure, arrhythmia, troponin rise)
  • Mononeuritis multiplex / foot or wrist drop
  • Gastrointestinal ischaemia or bleeding
  • Alveolar haemorrhage or rapidly progressive renal impairment

Assessment

Differential diagnosis

  • Severe eosinophilic asthma
  • Hypereosinophilic syndrome
  • ABPA
  • Other ANCA-associated vasculitides
  • Parasitic/drug-induced eosinophilia
  • Eosinophilic pneumonia

Investigations

  • Full blood count (marked eosinophilia)
  • ANCA (often MPO/p-ANCA positive in a subset)
  • HRCT chest (transient/peripheral infiltrates)
  • Nerve conduction studies for mononeuritis multiplex
  • Cardiac assessment (ECG, troponin, echo, cardiac MRI)
  • Tissue biopsy (eosinophilic vasculitis/granulomas) where feasible; urinalysis and renal function

Management

  • Suspect in asthma with eosinophilia and new multisystem features (neuropathy, cardiac, skin, GI)
  • Quantify eosinophilia and test ANCA
  • Map organ involvement, prioritising cardiac and neurological assessment
  • Obtain tissue confirmation where safe and feasible
  • Risk-stratify by major-organ (heart, nerve, kidney, GI) involvement
  • Induce remission with high-dose corticosteroids for all
  • Add cyclophosphamide or rituximab for severe/organ-threatening disease
  • Treat cardiac involvement urgently with cardiology input
  • Transition to maintenance immunosuppression and taper steroids
  • Use mepolizumab as a steroid-sparing agent in relapsing/refractory non-severe disease and follow long term

Drugs & doses

Prednisolone 1 mg/kg/day PO (up to 60 mg), with IV methylprednisolone pulses for organ-threatening disease
Cyclophosphamide (IV pulsed or oral) for severe/organ-threatening disease
Rituximab 375 mg/m2 weekly x4 or 1 g x2 as alternative induction
Mepolizumab 300 mg SC every 4 weeks (steroid-sparing, relapsing disease)
Azathioprine / methotrexate for maintenance

Disposition

Urgent rheumatology/respiratory vasculitis service; cardiology for cardiac disease; immunosuppression with specialist monitoring.

Complications & pitfalls

  • Cardiomyopathy and arrhythmia (leading cause of death)
  • Permanent peripheral neuropathy
  • Gastrointestinal perforation/ischaemia
  • Treatment-related infection and steroid toxicity

Exam pearls

  • Cardiac involvement is the main driver of mortality — assess the heart early
  • Only ~40% are ANCA-positive; a negative ANCA does not exclude EGPA
  • Mepolizumab is licensed as a steroid-sparing agent in relapsing/refractory EGPA
  • Beware EGPA unmasked during leukotriene-antagonist or biologic steroid tapering in asthma

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.